Table 3.
Procedural indices, outcomes, and operator volumes in the unmatched population.
| Variables | Total (n = 27,788) | 2 Operators (n = 3604) | 1 Operator (n = 24,184) | p-Value |
|---|---|---|---|---|
| Fractional flow reserve | 264 (1.0) | 37 (1.0) | 227 (0.9) | 0.61 |
| IVUS | 622 (2.2) | 92 (2.6) | 530 (2.2) | 0.17 |
| OCT | 81 (0.3) | 16 (0.4) | 65 (0.3) | 0.07 |
| Rotablation | 293 (1.1) | 29 (0.8) | 264 (1.1) | 0.12 |
| Mean TIMI grade after PCI | 2.16 ± 1.31 | 2.13 ± 1.33 | 2.17 ± 1.31 | 0.18 |
| TIMI grade after PCI | ||||
| 0 | 4752 (25.5) | 685 (26.6) | 4067 (25.3) | 0.52 |
| 1 | 418 (2.2) | 55 (2.1) | 363 (2.3) | |
| 2 | 473 (2.5) | 68 (2.6) | 405 (2.5) | |
| 3 | 12,978 (69.7) | 1763 (68.6) | 11,215 (69.9) | |
| TIMI grade 2/3 after PCI | 13,451 (72.2) | 1831 (71.2) | 11,620 (72.4) | 0.19 |
| Contrast volume, mL | 170 (120; 230) | 200 (150; 250) | 170 (120; 230) | <0.0001 |
| Radiation dose, Gy | 0.92 (0.50; 1.69) | 1.05 (0.62; 1.85) | 0.90 (0.48; 1.66) | <0.0001 |
| Vascular access | ||||
| Femoral | 7050 (25.4) | 1127 (31.3) | 5923 (24.5) | |
| Radial | 20,372 (73.4) | 2451 (68.1) | 17,921 (74.2) | <0.0001 |
| Other | 340 (1.2) | 24 (0.7) | 316 (1.3) | |
| Access site crossover | 536 (3.1) | 86 (3.9) | 450 (3.0) | 0.02 |
| PCI within bifurcation | 1939 (7.0) | 242 (6.7) | 1697 (7.0) | 0.51 |
| Type of stent implanted | ||||
| BMS | 323 (1.2) | 48 (1.3) | 275 (1.1) | 0.31 |
| BVS | 110 (0.4) | 24 (0.7) | 86 (0.4) | 0.006 |
| DES | 18,163 (65.4) | 2316 (64.3) | 15,847 (65.5) | 0.14 |
| Drug-eluting balloon | 677 (2.7) | 105 (3.2) | 572 (2.7) | 0.08 |
| Implanted stent | 18,549 (66.8) | 2382 (66.1) | 16,167 (66.9) | 0.37 |
| Number of implanted stents | ||||
| No stent used | 9239 (33.3) | 1222 (33.9) | 8017 (33.2) | |
| 1 | 14,640 (52.7) | 1873 (52.0 | 12,767 (52.8) | 0.73 |
| 2 | 3133 (11.3) | 413 (11.5) | 2720 (11.3) | |
| >2 | 776 (2.8) | 96 (2.7) | 680 (2.8) | |
| ASA | 7055 (25.4) | 927 (25.7) | 6128 (25.3) | 0.62 |
| UFH | 20,563 (74.0) | 2589 (71.8) | 17,974 (74.3) | 0.002 |
| LMWH | 784 (2.8) | 71 (2.0) | 713 (3.0) | <0.001 |
| Bivalirudin | 25 (0.1) | 5 (0.1) | 20 (0.1) | 0.30 |
| Thrombolysis during PCI | 19 (0.1) | 3 (0.1) | 16 (0.1) | 0.71 |
| Site volume total | 6548 (4748.00; 8602.00) | 6054 (4232.00; 8745.00) | 6747 (4843.00; 8602.00) | 0.04 |
| Site volume annual | 818.50 (593.50; 1075.25) | 756.75 (529.00; 1093.13) | 843.38 (605.38; 1075.25) | 0.04 |
| Operator volume total | 1617 (1096.00; 2261.00) | 1368 (857.25; 1970.25) | 1676 (1104.00; 2261.00) | <0.0001 |
| Annual operator volume | 202.13 (137.00; 282.63) | 171.00 (107.16; 246.28) | 209.50 (138.00; 282.63) | <0.0001 |
| Operator CTO volume total | 92.00 (39.00; 197.00) | 80.00 (30.00; 179.00) | 93.00 (40.00; 211.00) | <0.0001 |
| Operator CTO volume annual | 11.50 (4.88; 24.63) | 10.00 (3.75; 22.38) | 11.63 (5.00; 26.38) | <0.0001 |
Data are presented as median (first quartile, third quartile) or counts (percentages), if not stated otherwise. ASA, acetylsalicylic acid; BMS, bare-metal stent; BVS, bioresorbable vascular scaffold; CTO, chronic total occlusion; DES, drug-eluting stent; IVUS, intravascular ultrasound; LMWH, low molecular weight heparin; OCT, optical coherence tomography; PCI, percutaneous coronary intervention; TIMI, thrombolysis in myocardial infarction; UFH, unfractionated heparin.